Robert LeBoyer
Stock Analyst at Noble Capital Markets
(2.21)
# 2,693
Out of 4,876 analysts
18
Total ratings
43.75%
Success rate
9.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $35.54 | +96.96% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $7.83 | +66.03% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $0.95 | +952.63% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $5.94 | +910.10% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $10.28 | +483.66% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.75 | +263.64% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.74 | +704.60% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.96 | +729.62% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.37 | +32,633.22% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $12.35 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $9.57 | +25.39% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $825,000 | $0.84 | +98,566,208.24% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.55 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.44 | +336.05% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $35.54
Upside: +96.96%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $7.83
Upside: +66.03%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $0.95
Upside: +952.63%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $5.94
Upside: +910.10%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $10.28
Upside: +483.66%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.75
Upside: +263.64%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.74
Upside: +704.60%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.96
Upside: +729.62%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.37
Upside: +32,633.22%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.35
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $9.57
Upside: +25.39%
Aug 24, 2020
Initiates: Buy
Price Target: $825,000
Current: $0.84
Upside: +98,566,208.24%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $15.55
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.44
Upside: +336.05%